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Abstract
Objective To investigate the plasma levels of lopinavir by
enzyme-linked immunosorbent assay (ELISA) in a cohort of
patients who were vertically infected with human immunode-
ficiency virus 1 (HIV).
Methods Plasma levels of lopinavir (Cmin) were determined by
ELISA test in patients treated with lopinavir/ritonavir-based
combined antiretroviral therapy who had achieved virological
response after 4 wk of therapy. Reference lopinavir concentra-
tions were Cmin 1–8 μg/mL. Correlation between lopinavir
plasma concentration and continuous variables was evaluated
by mean of Pearson correlation coefficient. Differences in
lopinavir (LPV) concentration for binary categorical variables
were assessed by Mann-Whitney test, while for variables with
more than two categories Kruskal-Wallis test was used.
Results Thirty-four patients were enroled; median age was
133 mo (15–265). The median lopinavir dose tested was
383.5 mg/kg (IQR: 266.6–400 mg/kg), with a median plasma
concentration of 8.8 μg/mL (IQR: 5–14 μg/mL). Lopinavir
Cmin was <1 μg/mL in only one sample (2.9 %), while 14
samples had Cmin between 1 and 8 μg/mL (41.2 %) and 19
(55.9 %)>8 μg/mL. No significant correlations were found
between plasma concentrations of lopinavir and the continu-
ous variables considered in the study. A negative but, not
completely significant, correlation was found between plasma
drug concentration and body mass index (r=−0.29; p=0.09).
Conclusions The use of a simple and relatively cost-effective
methodology might render therapeutic drug monitoring
(TDM) appeal in the daily clinical practice.
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Introduction
The therapeutic drug monitoring (TDM) is a tool generally
used to monitor plasma drug levels of antiretroviral drugs,
being the plasma concentration of protease inhibitors (PIs) and
non-nucleosidic reverse transcriptase inhibitors (NNRTIs) as-
sociated with the levels of viral suppression and drug toxicity.
Unfortunately data about pharmacokinetics of these drugs in
pediatric patients are limited [1, 2].
TDM is also applicable to measure the adherence to the
therapy, allowing to check if the medication is actually taken
by the patient. United States and Europe HIV treatment guide-
lines recognize the potential benefit of TDM in selected
groups of patients, including children, pregnant women, pa-
tients with a change in physiologic state, potential for drug-
drug or food interaction, use of alternative dosage or drug
related toxicity [3, 4].
However, the standard TDM methodology, the high per-
formance liquid chromatography (HPLC), is expensive and
technically-demanding. An alternative method to check con-
centrations of the drugs in plasma samples is by enzyme-
linked immunosorbent assay (ELISA)-TDM, cheaper and
easier to perform than HPLC. The aim of the study was to
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evaluate the plasma levels of lopinavir (LPV) by TDM-
ELISA in a cohort of vertically HIV-infected patients.
Material and Methods
This was an open-label and descriptive study in children,
adolescents and young adults perinatally infected with HIV-
1. The authors defined children as those younger than 12 y,
adolescents 12 to 18 y and the young adults older than 18 y.
All patients who had achieved virological response after 4 wk
of combined antiretroviral therapy (cART) containing LPV/
ritonavir plus two nucleoside reverse transciptase inhibitors
(NRTIs) were included in the study. Virological response was
defined as viral load (VL) <50 copies/mL or decrease of >1
log10 in the first 4 wk of treatment.
Blood samples (5–7 mL) for pharmacokinetic evaluation
were drawn in EDTA-containing tubes. At the time of the
sample collection the patients, helped from parents or legal
guardians, filled an adherence questionnaire regarding adher-
ence during the last 4 d, modality of drugs consumption
(empty/full stomach, with adequate water intake), concomi-
tant medication, compliance to the therapeutic schedule.
In adolescents and young adults weighingmore than 40 kg,
dosage of LPV/ritonavir was 400/100 mg twice daily; in
children, 230 mg/57.5 mg LPV/r/m2 of body surface area
per dose twice daily.
LPV Cmin, were determined 4 wk after the initiation of the
therapy, to ensure steady-state plasma concentrations and all
samples were collected 30 min before the morning dose of
LPV/ritonavir (pre-dose). LPV Cmin were evaluated with
TDM ELISA, an immunoenzymatic test (Lopinavir TDM-
ELISA®, by Biostrands srl, Trieste, Italy), according to the
procedures described below and detailed in the lopinavir
TDM ELISA package insert [5]. TDM-ELISA technology is
based on a competition between the drug in plasma sample
and an analogue conjugated to the detecting enzyme. A spe-
cies–specific solid phase captures the specific antibody, while
excess sample and reagents are removed by washing. The
conjugate bound to the solid phase is detected by adding a
chromogen solution. The enzymatic activity produces a col-
ored solution whose adsorbance can be read by a microplate
reader at 450 nm. Absorbance values are inversely propor-
tional to the drug concentration on the sample. A calibration
curve is tested in exactly the same way, with the following
concentrations: −0.625 μg/mL, −2.5 μg/mL, −6.25 μg/mL,
−12.5 μg/mL, −25 μg/mL, −50 μg/mL; negative plasma
samples were included, the standard 0 was total binding.
The dynamic range for the LPV test is 1 to 8 μg/mL.
Statistical analysis was completed both for the real LPV
plasma concentration and for the LPV plasma concentration
divided in two classes (<=8 μg/mL and >8 μg/mL).
Correlation between continuous LPV plasma concentration
and continuous variables such as age in months, disease
duration, weight, body mass index (BMI), lymphocyte CD4
cell count, drug dosage, time between last dose and sampling
was evaluated by mean of Pearson correlation coefficient
while for number of tablets, Spearman’s rank correlation
coefficient was used.
Differences in LPV concentration for binary categorical
variables were assessed by mean of non-parametric Mann-
Whitney test, while for categorical variables with more than
two categories (i.e., : formulation) non-parametric Kruskal-
Wallis test was used.
The study protocol was approved by the local Institutional
Review Board of participating centres. Written informed con-
sent was obtained before study entry, and human experimen-
tation guidelines of the US Department of Health and Human
Services and/or those of the authors’ institutions were
followed.
Results
In one year of observation, a total of 34 HIV-infected young
patients naïve to LPV were enroled in the study. Twenty-five
patients (73.5 %) were Caucasians, 4 (11.8 %) were Africans,
4 (11,8 %) were Latin Americans, and 1 (2.9 %) was Asian.
All patients showed good immuno-virological response to
LPV-containing cART, with a decrease in viral load of ≥1
log10 in the first 4 wk of treatment. According to the Centers
for Disease Control classification, 13 (38.2 %) samples were
collected in patients who were in stage A (A1=5; A2=5 and
A3=3), 14 (41.2 %) were in stage B (B1=5; B2=5 and
B3=4), 6 (17.6 %) in stage C (C2=1 and C3=5) and 1
(3 %) in stage N (N2). The median age of patients was
133 mo (r=15–264 mo) and the weight ranges comprised
between 11 and 76 kg with median weight of 34.1 kg (IQR:
24.3–52), and median BMI of 17.6 kg/cm2 (IQR 16.2–20), as
showed in Table 1.
All patients received LPV in twice-daily regimen; tablet
formulation in 18 cases (53 %), capsules in 7 (20.6 %) and
syrup in 9 (26.4 %). A variety of antiretroviral combinations
were co-administered with LPV, including zidovudine/
lamivudine in 10 patients (29.4 %), tenofovir/lamivudine in
6 (17.6 %), abacavir/lamivudine in 6 (17.6 %), tenofovir/
emtricitabine in 5 (14.7 %) and other regimens in the
remaining seven patients (20.6 %).
The median time between last LPV dose and sample col-
lection was 12.5 h (IQR: 12–13 h) and median LPV dose
tested was 383.5 mg/m2 (IQR: 266.6–400 mg/m2), with a
median plasma concentration of 8.8 μg/mL (IQR: 5–14 μg/
mL). LPV plasma concentrations resulted erratic, with big
inter-patient variability: the average LPV Cmin of the cohort
was 9.2 μg/mL (SD=±4.96, r=0.6–18 μg/mL); in patients
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reporting complete adherence average LPV Cmin was 9.8 μg/
mL (SD=±4.94; r=0.6–18 μg/mL).
Among the 34 samples analyzed, LPV Cmin was <1 μg/mL
in only one samples (2.9 %), while 14 samples had Cmin
between 1 and 8 μg/mL (41.2 %) and 19 (55.9 %)>8 μg/mL.
Six out of 34 patients referred at least one omission to
therapy since the introduction of LPV in cART regimen, but
none of them had LPV concentration <1 μg/mL. The adher-
ence was complete in the remaining 28 cases (82.4 %),
according to the results of the questionnaires filled by patients.
The only patient with LPV Cmin<1 μg/mL did not refer
omissions and took the therapy on an empty stomach, the time
between the last dose and the moment in which the sample
was collected was 14 h in this case and the viremia was
undetectable.
Nine patients had detectable viremia after 4 wk of LPV
treatment; no significant correlations were found between
plasmatic concentration of LPV and the other continuous
variables considered in the study, such as age, length of
infection, weight, BMI, lymphocyte CD4 cell count, dosage
of LPV, time passed between last drug consumption and
plasma sampling. A negative but, not completely significant,
correlation was found between plasma drug concentration and
BMI (r=−0.29; p=0.09).
The non-parametric Kruskal Wallis test did not show sta-
tistically significant differences in LPV concentration among
ethnicities (p=0.340).
Higher LPV concentrations (>8 μg/mL) were found in the
majority of patients (19/34). Among them 14 received
lamivudine in the back-bone regimen, 9 received zidovudine,
5 tenofovir, 2 emtricitabine, 3 abacavir, 3 didanosine, 1 stav-
udine and 1 efavirenz,. A not completely significant difference
(p=0.09) was found between values of LPV plasma concen-
trations and assumption of didanosine (median : 14; IQR : 14–
14.6) compared to patients who did not take this drug (medi-
an: 8.1; IQR: 4.7–11). However only three of the patients
enroled in the study (8.8 %) took didanosine. No statistically
significant correlation was found between hours between
taking of LPV and blood sampling and LPV concentration.
Considering only subjects with a strict criteria of 12 h of
taking LPV/r, there are 15 patients with a mean LPV plasma
concentration of 8.71±4.65, as shown in Fig. 1. Also in this
Table 1 Demographic and clinical data of the study population at
baseline
Variable Median Range
Gender – no. (%)
Males 16 (45.7) – –
Female 19 (54.3) – –
Age (mo) 133 15–265
Weight (kg) 31 11–76
BMI 17 12–28
CD4+ (cells/mm3) 569 258–1,945
CD4+% 28 16–45
Viral load (copies/mL) <50 <40–33,000
LPV dosage (mg/kg) 368 200–800
LPV Cmin (μg/mL) 8.2 0.6–35.0
BMI Body mass index, LPV Lopinavir
Fig. 1 LPV concentrations in
samples and hour of collection
(only considering a subgroup of
15 patients)
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small subgroup, correlation between continuous LPV plasma
concentration and time between last dose and sampling as
assessed by mean of Pearson correlation coefficient did not
reveal any statistical significance (r=0.192; p=0.49).
Discussion
International, European, and US pediatric antiretroviral thera-
py guidelines recommend co-formulated protease inhibitor
lopinavir/ritonavir as a first-line PI agent for the treatment of
HIV infection in children and infants with a post-natal age of
at least 14 d [4, 6–8]. The recommended doses for children
who weigh more than 15 kg are 10 mg/kg of body weight or
230 mg/m2 (body surface area) twice daily, with a maximum
of 400 mg per dose unless it is combined with drugs affecting
cytochrome (CYP) P450 metabolism, which require LPV
dose adjustment [4].
Models of pharmacokinetics of LPV in children have been
developed on the basis of weight and age of patients [9–12].
However, the absolute bioavailability of LPV co-formulated
with ritonavir in humans has not yet been established [13].
A variety of factors can interact with LPV plasma concen-
tration. The administration of the drug with a moderate fatty
food for example may increase its adsorption [13].
Conversely, a factor potentially causing a decrease in plas-
ma LPV concentrations is its hepatic inactivation made by the
cytochrome CYP 3A4, partially inhibited by ritonavir co-
formulation.
Another factor influencing the kinetics of the drug is its
high plasma protein binding: at steady state, LPV is 98–99 %
plasma protein bound, involving possible interactions with a
multitude of drugs binding plasma proteins too.
In the index study, no patient took other drugs or had co-
morbidities affecting the ability to metabolize the drug.
However, from the analysis, inter-individual variability in
drug concentration resulted high and no factor associated
significantly with drug concentration was found. These data
led the authors to think that therapeutic drug monitoring
should have a relevant role in routine monitoring of patients
taking LPV.
The use of TDM in the management of patients infected
with HIV has been widely studied, and well accepted by the
patients [14–18]. TDM is a valid clinical method to avoid over
or under-dosage of drugs and also to monitor compliance, in
order to optimize the treatment for each patient and avoid side
effects.
Besides, it could also be a useful tool to monitor which
patients may be eligible for once-daily drug regimens [19].
Nevertheless, few data are available on TDM use in children
and adolescents [12, 18, 20, 21]. High performance liquid
chromatographic method remains the standard of care in
TDM, but it is a technically-demanding and time consuming
procedure, available in few laboratories and run by specifically
trained expert personnel. The TDM ELISA method overcomes
problems associated with peripheral HIV centers’ lacking of
access to pharmacokinetic test.
High inter-individual variability in trough levels of LPV
was found, as already observed in all patients treated with PIs
[22].
In patients with a difficult approach to cART, such as
children, adolescents and young adults, TDM may also have
a role in monitoring adherence during routine clinical practice.
In fact, the adherence to HIV medication regimens is often
suboptimal in young patients and decreases progressively
when children reach adolescence, [23–26] due to a multitude
of factors, such as lack of family support, denial and fear of
HIV infection, lack of belief in the effectiveness of medica-
tions, regimen fatigue, adverse effects and fear of stigmatiza-
tion [25, 27–32].
The main limitations of the present study were the small
size of study population, the exclusion of patients which did
not meet the criteria for viral response and those pre-treated
with other PIs. Furthermore, the results were not compared
with the gold standard TDM methodology represented by
HPLC.
The use of a simple and relatively cost-effective method-
ology might render TDM feasible in the daily clinical practice
of HIV-infected youths.
Conclusions
TDM ELISA testing could be a reliable and useful method for
routine monitoring of drug plasma levels, since it is easy to
perform in any laboratory and could be a valid clinical tool to
avoid over or under-dosage of drugs and also to monitor
compliance, in order to optimize the treatment for each patient
and avoid side effects.
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